Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...
People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing acute myeloid leukemia (AML), an aggressive form of blood cancer. Scientists have now identified the ...
The review sheds light on the role of post-transcriptional RNA modifications in normal hematopoietic development and acute myeloid leukemia, and highlights novel therapeutic targets and treatment ...
Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...
Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...
Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.
People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukaemia (AML), an aggressive form of blood cancer. Scientists led by the Department of ...
Treatment of older patients with AML involves complex decisions taking into consideration age, fitness, treatment tolerability, quality of life, and social support. Increased treatment options have ...
A bone marrow or stem cell transplant may be beneficial for people with intermediate- to high-risk acute myeloid leukemia (AML) who are in remission and can tolerate an intensive treatment plan. Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results